Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2004-12-21
2010-06-29
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S208100, C435S325000
Reexamination Certificate
active
07744897
ABSTRACT:
HIV gp41 mimetibody polypeptides and encoding polynucleotides are disclosed. Methods of utilizing the polypeptides to reduce or inhibit HIV fusion with a cell membrane and entry into target cells are also disclosed.
REFERENCES:
patent: 5817767 (1998-10-01), Allaway et al.
patent: 2004/0171542 (2004-09-01), Bailon et al.
patent: WO 94/02505 (1994-02-01), None
patent: WO 94/28920 (1994-12-01), None
patent: WO 96/19495 (1996-06-01), None
patent: WO 99/59615 (1999-11-01), None
patent: WO 01/03723 (2001-01-01), None
patent: WO 01/51673 (2001-07-01), None
patent: WO 01/07081 (2002-02-01), None
patent: WO 02/103026 (2002-12-01), None
patent: WO 03/016333 (2003-02-01), None
patent: WO 03/066078 (2003-08-01), None
patent: WO 03/084477 (2003-10-01), None
patent: WO 2004/002424 (2004-01-01), None
patent: WO2004/029074 (2004-04-01), None
patent: WO2004/029074 (2004-04-01), None
patent: WO 2004/106364 (2004-12-01), None
Frazer, J. K., and J. D. Capra, 1999, “Immunoglobulins: Structure and Function”, in Fundamental Immunology, Fourth Edition, W. E. Paul, ed., Lippincott-Raven Publishers, Philadelphia, pp. 41, 43,44, 46-49, and 54.
Max, E. E., 1999, “Immunoglobulins: Molecular Genetics”, in Fundamental Immunology, Fourth Edition, W. E. Paul, ed., Lippincott-Raven Publishers, Philadelphia, pp. 142-143.
Braren, I., et al., 2007, “Comparative expression of different antibody formats in mammalian cells andPichia pastoris”, Biotechnol. Appl. Biochem. 47:205-214.
Geng, S., et al., 2007, “Human IgG1 Cgamma1 domain is crucial for the bioactivity of the engineered anti-CD20 antobidies”, Cell. Mol. Immunol. 4(2):121-125.
Gallaher, et al., “A General Model for the Transmembrane Proteins of HIV and Other Retroviruses,”AIDS Research and Human Retroviruses, 5(4): 431-440 (1989).
Delwart, et al., “Retroviral Envelope Glycoproteins Contain a “Leucine Zipper”-like Repeat,”AIDS Research and Human Retroviruses, 6(6): 703-706 (1990).
Wild, et al., “A Synthetic Peptide from HIV-1 gp41 is a Potent Inhibitor of Virus-Mediated Cell-Cell Fusion,”AIDS Research and Human Retroviruses, 9(11): 1051-1053 (1993).
Dubay, et al., “Mutations in the Leucine Zipper of the Human Immunodeficiency Virus Type 1 Transmembrane Glycoprotein Affect Fusion and Infectivity,”Journal of Virology, 66(8): 4748-4756 (1992).
Jiang, et al., “Peptide and Non-peptide HIV Fusion Inhibitors,”Current Pharmaceutical Design, 8: 563-580 (2002).
Dragic, et al., “HIV-1 entry into CD4+cells is mediated by the chemokine receptor CC-CKR-5,”Nature, 381: 667-673 (1996).
Deng, et al., “Identification of a major co-receptor for primary isolates of HIV-1,”Nature, 381: 661-666 (1996).
Feng, et al., “HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane G Protein-Coupled Receptor,”Science, 272: 872-877 (1996).
Eron, et al., “Entry and Fusion Inhibitors: an Update,”The PRN Notebook, 7(1): 16-22 (2002).
Kilby, et al., “Novel therapies Based on Mechanisms of HIV-1 Cell Entry,”New England Journal of Medicine, 348(22): 2228-2238 (2003).
Eron, et al., “Short-Term Safety and Antiretroviral Activity of T-1249, a Second-Generation Fusion Inhibitor of HIV,”JID, 189: 1075-1083 (2004).
Tan, et al., “Atomic structure of a thermostable subdomain of HIA-1 gp41,”Proceedings of the National Academy of Science USA, 94: 12303-12308 (1997).
Weissenhorn, et al., “Atomic structure of the ectodomain from HIV-1 gp41,”Nature, 387: 426-430 (1997).
Chan, et al., “Core Structure of gp41 from the HIV Envelope Glycoprotein,”Cell, 89: 263-273 (1997).
Wild, et al., “Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex,”Proceedings of the National Academy of Science USA, 91: 12676-12680 (1994).
Kilby, et al., “Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry,”Nature Medicine, 4(11): 1302-1307 (1998).
PCT International Search Report dated Jun. 21, 2005.
Supplementary EP Search Report dated Sep. 25, 2007.
Ruprecht, et al., “Antibody protection: passive immunization of neonates against oral AIDS virus challenge,” 21: 3370-3373 (2003).
Del Vecchio Alfred Michael
Dillon Susan B.
Huang Chichi
O'Neil Karyn T.
Sarisky Robert T.
Baumeister Kirk
Parkin Jeffrey S.
LandOfFree
Human immunodeficiency virus gp41 mimetibody polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human immunodeficiency virus gp41 mimetibody polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human immunodeficiency virus gp41 mimetibody polypeptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4244887